<DOC>
	<DOCNO>NCT02591277</DOCNO>
	<brief_summary>This study evaluate safety efficacy Harvoni® ( ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) ) treatment real world use Japan . Among adult patient chronic genotype 1 hepatitis C virus ( HCV ) infection treat Harvoni routine clinical use , primary objective study evaluate incidence adverse drug reaction ( ADRs ) real world setting .</brief_summary>
	<brief_title>Use-Results Surveillance Study Harvoni® Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Adult patient chronic genotype 1 HCV infection without compensated cirrhosis Patients prescribed Harvoni Key Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>observational</keyword>
	<keyword>post-marketing</keyword>
	<keyword>ledipasvir/sofosbuvir</keyword>
	<keyword>Japan</keyword>
</DOC>